Triggering PIK3CA Mutations in PI3K/Akt/mTOR Axis: Exploration of Newer Inhibitors and Rational Preventive Strategies

Asati Vivek; Bharti Sanjay K.; Mahapatra Debarshi Kar; Asati Vikas; Budhwani Ashok K.

首页> 外文期刊>Current pharmaceutical design >Triggering PIK3CA Mutations in PI3K/Akt/mTOR Axis: Exploration of Newer Inhibitors and Rational Preventive Strategies

【24h】

Triggering PIK3CA Mutations in PI3K/Akt/mTOR Axis: Exploration of Newer Inhibitors and Rational Preventive Strategies

机译：触发PI3K / Akt / mTOR轴中的PIK3CA突变：新型抑制剂的探索和合理的预防策略

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: PIK3CA gene was found in generation of p110 alpha (p110a) protein through an instruction process. p110 alpha acts as a catalytic subunit of phosphatidylinositol 3-kinase (PI3K) proceed phosphorylation of signal molecules through PI3K pathway. This PI3K involved in regulation of cellular growth, transformation, adhesion, apoptosis, survival and motility. In some situations the PI3K/Akt pathway get altered due to mutation in PIK3CA gene produced oncogenic event in human malignancy.

机译：背景：PIK3CA基因是通过指导过程在p110 alpha（p110a）蛋白的产生中发现的。 p110α充当磷脂酰肌醇3-激酶（PI3K）的催化亚基，通过PI3K途径进行信号分子的磷酸化。该PI3K参与细胞生长，转化，粘附，凋亡，存活和运动的调节。在某些情况下，PI3K / Akt途径由于人恶性肿瘤中产生的致癌事件的PIK3CA基因突变而改变。

著录项

来源
《Current pharmaceutical design》 |2016年第39期|共16页
作者
Asati Vivek; Bharti Sanjay K.; Mahapatra Debarshi Kar; Asati Vikas; Budhwani Ashok K.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词
PI3K/PTEN/Akt; PIK3CA; Signaling pathway; Anticancer; Inhibitors;

机译：PI3K / PTEN / Akt;PIK3CA;信号通路;抗癌;抑制剂;

相似文献

外文文献
中文文献
专利

1. Triggering PIK3CA Mutations in PI3K/Akt/mTOR Axis: Exploration of Newer Inhibitors and Rational Preventive Strategies [J] . Asati Vivek, Bharti Sanjay K., Mahapatra Debarshi Kar, Current pharmaceutical design . 2016,第39期

机译：触发PI3K / Akt / mTOR轴中的PIK3CA突变：新型抑制剂的探索和合理的预防策略
2. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations [J] . JankuF., WhelerJ.J., WestinS.N., Journal of Clinical Oncology . 2012,第8期

机译：PI3K / AKT / mTOR抑制剂在具有PIK3CA突变的乳腺癌和妇科恶性肿瘤患者中
3. 253 Screening for PIK3CA, RAS, and {RAF} mutations in trials with PI3K/AKT/mTOR signaling pathway inhibitors [J] . F. Janku, A.M. Tsimberidou, I. Garrido-Laguna, European Journal of Cancer Supplements . 2010,第7期

机译：253在使用PI3K / AKT / mTOR信号通路抑制剂的试验中筛选PIK3CA，RAS和 {RAF }突变
4. Combination of PI3K/Akt/mTOR inhibitors and PDT in endothelial and tumor cells. [C] . Fateye, Babasola, Chen Bin Optical methods for tumor treatment and detection: mechanisms and techniques in photodynamic therapy XX . 2011

机译：内皮细胞和肿瘤细胞中PI3K / Akt / mTOR抑制剂和PDT的组合。
5. Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-Clinical Mechanistic Assessment [D] . Moorthy, Ganesh P. 2015

机译：BEZ235，PI3K / mTOR抑制剂和依维莫司，mTOR抑制剂的新型组合的临床药代动力学：I期临床研究和非临床机制评估
6. PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors [O] . Filip Janku, Apostolia M. Tsimberidou, Ignacio Garrido-Laguna, -1

机译：用PI3K / AKT / MTOR轴抑制剂治疗晚期癌症患者的PIK3CA突变
7. PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway [O] . Huayu Hu, Junyong Zhu, Yuting Zhong, 2021

机译：Pik3CA突变通过抑制细胞凋亡并激活PI3K / AKT / MTOR信号传导途径来赋予三重阴性乳腺癌化疗的抵抗力

Triggering PIK3CA Mutations in PI3K/Akt/mTOR Axis: Exploration of Newer Inhibitors and Rational Preventive Strategies

摘要

著录项

相似文献

相关主题

期刊订阅